| Aarti Drugs Limited was incorporated on 28th September, 1984 as a Private Limited Company. It was converted into a Public Limited Company on 1st July, 1992.
The Company is presently engaged in the manufacture of MNI(300 TPA), MTZ (96 TPA), TNZ (84 TPA), DMZ (90 TPA) and Isoniazid (INH) (96 TPA). The Company started its commercial production is March 1987 at G.I.D.C. Industrial Estate, Sarigam, Dist. Valsad, Gujarat. This project was put up with financial assistance from Gujarat State Finance Corporation (GSFC) and Gujarat Industrial Investment Corporation (GIIC).
The Company now proposes to expand the capacities for the above products, except INH and also proposes to set up a new plant for the manufacture of Glyoxal and Ammonium Sulphate. The Company has been consistently making profits and has maintained an unbroken dividend record since the year 1990-91.
The Company is a part of the Alchemie Group of Companies. The Company is promoted by Mr. Chandrakant V.Gogri, Mr.Rajendra V.Gogri and Mr. Shantilal T. Shah. Mr. P.M. Patil and Mr. S. P. Nachane joined the Group in 1981. The Alchemie Group is a professionally managed, multi-product, multilocation Group comprising 24 manufacturing units with a total turnover of over Rs.100
crores for the year 1991-92. The products of the Group, exceeding 40, range from industrial chemicals and dye intermediates to bulk drugs and fine chemicals. The Group's customer list includes most of the leading chemical companies in the country. The Group's turnover and profits have increased five-fold in the last 5 years. It also recorded an export turnover of more than Rs. 30 crores in the year 1991-92. The Group units export products mainly to the general currency areas such as USA, UK, Switzerland and Germany.
2000 - The Company proposed to acquire 15,31,000 No. of equity shares of
Alchemie Organics Ltd 33.44 per cent of the total paid-up capital of AOL
held by the other promoters.
2002-Gauri Balankhe appointed as Compliance Officer of Aarti Drugs.
2004
-Aarti Drugs Ltd. has informed that the Company has changed its Registrar and Share Transfer Agent and Depository interface for Handling Depository related operations by appointing M/s Sharepro Services in place of M/s R & D Consultants Ltd w.e.f. January 16, 2004 subject to completion of necessary formalities as maybe prescribed in this regard. The address and telephone number of M/s Sharepro Services for all investors related services are as under: 1. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Raheja Centre, Free Press Journal Road, Nariman Point, Mumbai 400 021, Tel nos : 22881569, 22884527. 2. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Satam Estate, 3rd Floor, Above Bank of Baroda, Chakla, Andheri (East), Mumbai 400 099, Tel nos : 28215168, 28319828; Fax nos : 28375646.
-Aarti bags European certification for three drugs
-Delist from Ahmedabad Stock Exchange (ASE) with effect from October 15, 2004.
2006
-Aarti Drugs enters into JV with API Manufacturing Chinese Company
- Aarti Drugs Ltd. has informed that Mr. Prakash Khedekar, Company Secretary & Compliance Officer of the Company has resigned from the position of Company Secretary & Compliance Officer with effect from October 31, 2006. Further, Mrs. Mona Patel, possessing requisite qualifications, has been appointed as Company Secretary & Compliance Officer of the Company with effect from November 01, 2006.
2009
- Aarti Drugs Ltd has has appointed Shri Krishnacharya Govindacharya Akamanchi & Prof. Sudhir Prakash B. Sawant as Independent Directors of the Company.
2010
-Aarti Drugs has recommended dividend of Rs. 5/- (50%) per share
2011
-Mr. Sunny D. Pagare, has been appointed as Company Secretary & Compliance Officer of the Company
-Aarti Drugs has recommended Final Dividend of Rs. 2.5 /-per share (25%)
2012
-Mr. Adhish P. Patil, has been appointed as Chief Financial Officer of the Company
-Aarti Drugs has declared Final dividend Rs. 3.00 (30%) per share
2013
-Aarti Drugs has recommended a Final Dividend of Rs. 4/- per share on Equity Shares of Rs. 10/- each.
2014
-Aarti Drugs has commenced the new R&D center at MIDC Tarapur.
-Aarti Drugs has recommended a Final dividend @ Rs. 5.50 ps. (55%) per share.
2015
-Aarti Drugs Ltd has will participate at 'Centrum Pharma Day' Investor Conference
-The Company has allotted the Bonus Shares to its shareholders in the Ratio of 1:1.
2020
-The Company has issued Bonus Shares in the Ratio of 3:1.
2023
-Aarti Drugs Limited won Pharmexcil Outstanding Exports Awards 2021-22"".
2024
-The Company Initiating Commercial Production of Dermatology Product at New Facility in Tarapur, Maharashtra"".
2025
-Aarti Drugs Limited has informed the Exchange about Commencement of commercial production/operation.
|